Nitrogen ( DrugBank: Nitrogen )

6 diseases

ID	Disease name (Link within this page)	Number of trials
5	Progressive supranuclear palsy	1
6	Parkinson disease	1
17	Multiple system atrophy	1
171	Wilson disease	1
211	Hypoplastic left heart syndrome	1
299	Cystic fibrosis	2

5. Progressive supranuclear palsy

Clinical trials : 95 / Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008959	2012/11/01	16/10/2012	Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy		Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP)	hydrogen water pseudo-water (nitrogen filling water)	Juntendo University School of Medicine, Department of Neurology	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	40	Phase 1	Japan

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000010014	2013/02/28	13/02/2013	Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease		Parkinson's disesase	hydrogen water made by "Suisosui5.0" placebo-water (nitrogen filling water)	Juntendo University School of Medicine, Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	200	Not selected	Japan

Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008959	2012/11/01	16/10/2012	Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy		Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP)	hydrogen water pseudo-water (nitrogen filling water)	Juntendo University School of Medicine, Department of Neurology	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	40	Phase 1	Japan

Clinical trials : 68 / Drugs : 79 - (DrugBank : 17) / Drug target genes : 3 - Drug target pathways : 28

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02702765 (ClinicalTrials.gov)	February 2016	26/2/2016	sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis	Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis	Wilsons Disease	Procedure: Fibroscan;Procedure: Ultrasound;Drug: Galactose;Procedure: Liver biopsy;Procedure: Functional hepatic nitrogen clearance	University of Aarhus	Aarhus University Hospital	Active, not recruiting	18 Years	100 Years	All	33	N/A	Denmark

Clinical trials : 21 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000017311	2015/05/01	01/05/2015	Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease.	Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. - Hypoxia inhalation therapy for infants	hypoplastic left heart syndrome, coarctation of aorta, interruption of aorta, truncus arteriosus, double outlet of right ventricle (Taussig-Bing anomaly), single ventricles	Hypoxia inhalation nitrogen inhalation	Institutional Review Board of Kagoshima University	NULL	Pending	1days-old	365days-old	Male and Female	30	Not selected	Japan

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02950116 (ClinicalTrials.gov)	March 9, 2017	11/10/2016	Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease	Lung Clearance Index in Pediatric Patients With Obstructive Lung Disease	Asthma;Bronchiectasis;Cystic Fibrosis	Device: Perform three multiple breath nitrogen washout tests (N2-MBW-test)	Universitair Ziekenhuis Brussel	NULL	Terminated	6 Years	17 Years	All	27	N/A	Belgium
2	NCT00570349 (ClinicalTrials.gov)	July 2004	6/12/2007	Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Nitric Oxide for Inhalation;Drug: Nitrogen	Mallinckrodt	NULL	Completed	12 Years	N/A	All	18	Phase 1/Phase 2	United States